The maker of Clear Eyes voluntarily pulled nearly 40,000 bottles of its “Maximum Itchy Eye Relief” from shelves Tuesday. Prestige Consumer Healthcare wrote down the unsterile batches after federal regulators stubbornly refused to see the long-term value of introducing new bacteria directly into consumers' corneas.
Prestige Consumer Healthcare executives characterized the recall as a minor regulatory hurdle, noting that the FDA’s rigid insistence on an "assurance of sterility" fundamentally misunderstands the consumer health giant's growth model. By shipping drops that actively cultivate fresh microbial colonies on the surface of the eye, analysts noted the company had effectively guaranteed a captive, heavily weeping market for its subsequent product lines, bypassing the need to wait for seasonal allergies to drive sales.
A perfectly sterile product resolves the customer's irritation and ends the transaction, whereas a product lacking basic sterility assurance builds a recurring revenue relationship with that eye for weeks to come.
Shares of the company dipped slightly on the news that it would have to return to manufacturing drops that do not proactively cause the ailments they treat. During an afternoon earnings call, leadership expressed frustration that the FDA's demand for a sterile manufacturing environment adds millions in overhead that could otherwise be deployed toward shareholder value and stock buybacks. They confirmed the 40,000 bottles would be destroyed rather than repurposed for the company's emerging pink-eye division.
At the close of trading in New York, Prestige updated its forward guidance to reassure investors that, despite the unexpected recall, standard air pollution and extended screen time would still provide sufficient demand for the ocular relief portfolio through the fourth quarter.